197 related articles for article (PubMed ID: 19548350)
1. Effect of intestinal glucuronidation in limiting hepatic exposure and bioactivation of raloxifene in humans and rats.
Dalvie D; Kang P; Zientek M; Xiang C; Zhou S; Obach RS
Chem Res Toxicol; 2008 Dec; 21(12):2260-71. PubMed ID: 19548350
[TBL] [Abstract][Full Text] [Related]
2. Intestinal glucuronidation metabolism may have a greater impact on oral bioavailability than hepatic glucuronidation metabolism in humans: a study with raloxifene, substrate for UGT1A1, 1A8, 1A9, and 1A10.
Mizuma T
Int J Pharm; 2009 Aug; 378(1-2):140-1. PubMed ID: 19486934
[TBL] [Abstract][Full Text] [Related]
3. Prediction of human drug clearance by multiple metabolic pathways: integration of hepatic and intestinal microsomal and cytosolic data.
Cubitt HE; Houston JB; Galetin A
Drug Metab Dispos; 2011 May; 39(5):864-73. PubMed ID: 21303923
[TBL] [Abstract][Full Text] [Related]
4. Raloxifene glucuronidation in liver and intestinal microsomes of humans and monkeys: contribution of UGT1A1, UGT1A8 and UGT1A9.
Kishi N; Takasuka A; Kokawa Y; Isobe T; Taguchi M; Shigeyama M; Murata M; Suno M; Hanioka N
Xenobiotica; 2016; 46(4):289-95. PubMed ID: 26247833
[TBL] [Abstract][Full Text] [Related]
5. Differences between human and rat intestinal and hepatic bisphenol A glucuronidation and the influence of alamethicin on in vitro kinetic measurements.
Mazur CS; Kenneke JF; Hess-Wilson JK; Lipscomb JC
Drug Metab Dispos; 2010 Dec; 38(12):2232-8. PubMed ID: 20736320
[TBL] [Abstract][Full Text] [Related]
6. Characterization of raloxifene glucuronidation in vitro: contribution of intestinal metabolism to presystemic clearance.
Kemp DC; Fan PW; Stevens JC
Drug Metab Dispos; 2002 Jun; 30(6):694-700. PubMed ID: 12019197
[TBL] [Abstract][Full Text] [Related]
7. The role of pH in the glucuronidation of raloxifene, mycophenolic acid and ezetimibe.
Chang JH; Yoo P; Lee T; Klopf W; Takao D
Mol Pharm; 2009; 6(4):1216-27. PubMed ID: 19449843
[TBL] [Abstract][Full Text] [Related]
8. NADPH-dependent covalent binding of [3H]paroxetine to human liver microsomes and S-9 fractions: identification of an electrophilic quinone metabolite of paroxetine.
Zhao SX; Dalvie DK; Kelly JM; Soglia JR; Frederick KS; Smith EB; Obach RS; Kalgutkar AS
Chem Res Toxicol; 2007 Nov; 20(11):1649-57. PubMed ID: 17907785
[TBL] [Abstract][Full Text] [Related]
9. Raloxifene glucuronidation in human intestine, kidney, and liver microsomes and in human liver microsomes genotyped for the UGT1A1*28 polymorphism.
Trdan Lusin T; Trontelj J; Mrhar A
Drug Metab Dispos; 2011 Dec; 39(12):2347-54. PubMed ID: 21937736
[TBL] [Abstract][Full Text] [Related]
10. Detoxication versus Bioactivation Pathways of Lapatinib In Vitro: UGT1A1 Catalyzes the Hepatic Glucuronidation of Debenzylated Lapatinib.
Nardone-White DT; Bissada JE; Abouda AA; Jackson KD
Drug Metab Dispos; 2021 Mar; 49(3):233-244. PubMed ID: 33376146
[No Abstract] [Full Text] [Related]
11. Extensive intestinal glucuronidation of raloxifene in vivo in pigs and impact for oral drug delivery.
Thörn HA; Yasin M; Dickinson PA; Lennernäs H
Xenobiotica; 2012 Sep; 42(9):917-28. PubMed ID: 22559211
[TBL] [Abstract][Full Text] [Related]
12. Hepatic and intestinal glucuronidation of mono(2-ethylhexyl) phthalate, an active metabolite of di(2-ethylhexyl) phthalate, in humans, dogs, rats, and mice: an in vitro analysis using microsomal fractions.
Hanioka N; Isobe T; Kinashi Y; Tanaka-Kagawa T; Jinno H
Arch Toxicol; 2016 Jul; 90(7):1651-7. PubMed ID: 26514348
[TBL] [Abstract][Full Text] [Related]
13. Species- and disposition model-dependent metabolism of raloxifene in gut and liver: role of UGT1A10.
Jeong EJ; Liu Y; Lin H; Hu M
Drug Metab Dispos; 2005 Jun; 33(6):785-94. PubMed ID: 15769887
[TBL] [Abstract][Full Text] [Related]
14. Role of hepatic metabolism in the bioactivation and detoxication of amodiaquine.
Jewell H; Maggs JL; Harrison AC; O'Neill PM; Ruscoe JE; Park BK
Xenobiotica; 1995 Feb; 25(2):199-217. PubMed ID: 7618347
[TBL] [Abstract][Full Text] [Related]
15. Impact of intestinal glucuronidation on the pharmacokinetics of raloxifene.
Kosaka K; Sakai N; Endo Y; Fukuhara Y; Tsuda-Tsukimoto M; Ohtsuka T; Kino I; Tanimoto T; Takeba N; Takahashi M; Kume T
Drug Metab Dispos; 2011 Sep; 39(9):1495-502. PubMed ID: 21646435
[TBL] [Abstract][Full Text] [Related]
16. Evidence for the bioactivation of zomepirac and tolmetin by an oxidative pathway: identification of glutathione adducts in vitro in human liver microsomes and in vivo in rats.
Chen Q; Doss GA; Tung EC; Liu W; Tang YS; Braun MP; Didolkar V; Strauss JR; Wang RW; Stearns RA; Evans DC; Baillie TA; Tang W
Drug Metab Dispos; 2006 Jan; 34(1):145-51. PubMed ID: 16251255
[TBL] [Abstract][Full Text] [Related]
17. Metabolism of the nephrotoxicant N-(3,5-dichlorophenyl)succinimide in rats: evidence for bioactivation through alcohol-O-glucuronidation and O-sulfation.
Cui D; Rankin GO; Harvison PJ
Chem Res Toxicol; 2005 Jun; 18(6):991-1003. PubMed ID: 15962934
[TBL] [Abstract][Full Text] [Related]
18. Differences in cytochrome P450-mediated biotransformation of 1,2-dichlorobenzene by rat and man: implications for human risk assessment.
Hissink AM; Oudshoorn MJ; Van Ommen B; Haenen GR; Van Bladeren PJ
Chem Res Toxicol; 1996 Dec; 9(8):1249-56. PubMed ID: 8951226
[TBL] [Abstract][Full Text] [Related]
19. Effect of hyperthyroidism on the in vitro metabolism and covalent binding of 1,1-dichloroethylene in rat liver microsomes.
Gunasena GH; Kanz MF
J Toxicol Environ Health; 1997 Oct; 52(2):169-88. PubMed ID: 9310148
[TBL] [Abstract][Full Text] [Related]
20. Glucuronidation of curcuminoids by human microsomal and recombinant UDP-glucuronosyltransferases.
Hoehle SI; Pfeiffer E; Metzler M
Mol Nutr Food Res; 2007 Aug; 51(8):932-8. PubMed ID: 17628876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
